Impeding communication between cancer tissue, immune cells with new molecule — ScienceDaily
source : http://www.sciencedaily.com/releases/2014/01/140129114932.htm
source : http://www.sciencedaily.com/releases/2014/01/140129114932.htm
source : http://www.sciencedaily.com/releases/2014/01/140129115205.htm
source : http://www.sciencedaily.com/releases/2014/01/140128163457.htm
source : http://www.sciencedaily.com/releases/2013/12/131217134706.htm
source : http://www.sciencedaily.com/releases/2014/01/140121151647.htm
Bladder cancer is the fourth most common non-skin cancer. But there is no good screening test for it, and there has been limited progress in characterizing how aggressive an individual’s bladder cancer will be. Loyola researchers studied microscopic droplets, called exosomes, that are shed by cancer cells and are found in urine. Understanding the biology of exosomes could lead to the development of a screening test, which would require a simple urine sample, said lead researcher Gopal Gupta, MD. …
"Cervical cancer is a huge problem worldwide, but isn’t as big a problem in the United States. So in many ways it tends to become a somewhat overlooked and under-studied disease," says Tracey Schefter, MD, investigator at the University of Colorado Cancer Center, director of the Stereotactic Body Radiation Therapy program at the University of Colorado School of Medicine, and the study’s lead author…
In the United States, uterine cancer is the fourth most common cancer in women, with an estimated 49,560 women diagnosed in 2013. In addition to surgery, 38 percent of patients undergo pelvic radiation therapy to decrease uterine cancer recurrence…
"NeoALTTO is a randomized, phase III clinical trial evaluating whether a combination of two HER2-targeted therapies, trastuzumab and lapatinib, given with standard paclitaxel chemotherapy before surgery [neoadjuvant therapy] is better than just one of the HER2-targeted therapies given with the same chemotherapy," said Martine Piccart-Gebhart, M.D., Ph.D., chair of the Breast International Group (BIG) in Brussels, Belgium. …
The (REiNS) Collaboration was formed to achieve consensus regarding the design of clinical trials for treatments of NF and related disorders, with a focus on developing a standard set of appropriate and meaningful outcome measures. "This supplement presents the initial progress of several of the working groups and includes the first series of consensus recommendations for NF clinical trial endpoints by the REiNS International Collaboration," according to an introduction by Dr Scott R. …